Last update: July 31, 2018
Minimal risk for breastfeeding and infant.
An immunomodulator and calcineurin inhibitor related to tacrolimus. Used in the treatment of atopic dermatitis.
Used topically as a cream and orally in research studies.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (moderately high molecular weight, high percentage of protein binding and very little systemic absorption with topical use (less than 2 micrograms/L in plasma) (AEMPS 2013, FDA 2001) make it unlikely that will be transferred to milk in significant quantities (AEMPS 2013).
Do not apply on the breast in order to prevent the infant from swallowing it (AEMPS 2013, Barret 2013, Butler 2014); if necessary, apply after a feed and clean well with water before the next feed.
It is advisable to avoid the application of creams, gels and other local application products containing paraffin (mineral oil) on the nipple so that the infant does not absorb them (Noti 2003, Concin 2008).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM